🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What’s the role of anti-CTLA-4 in #NSCLC patients with brain metastases? Hear Jordi Remon share his current approach and future outlook with Solange Peters & Patrick Forde. Watch the full roundtable on demand ⬇️

We have three TKIs: firmonertinib, sunvozertinib, and zipalertinib, with FDA breakthrough designation (BTD) for EGFR Ex20ins NSCLC patients. We will change the SoC landscape soon for this patient population! EGFR Resisters Exon 20 Group, a multistakeholder organization Eric K. Singhi, MD I cannot wait to debate among

🔝🔝Al II retreat unitat funcional tumors toracics Hospital Clínic

Hem compartit una jornada fantàstica amb companys de múltiples especialitats. Treballar plegats és el que ens fa créixer com a equip i millorar l’atenció als pacients amb càncer de pulmó. #TreballEnEquip #UnitatDePulmó #Retreat Hospital Clínic

FDA approval of taletrectinib in #ROS1 NSCLC has immediate impact on patients with this subset of lung cancer. Discussion with Drs. Jorge Nieva and Enriqueta Felip in this episode of the IASLC podcast, Lung Cancer Considered. iaslc.org/iaslc-news/lun…

Panel and video highlights from #ASCO25 now available from high5md with Drs. Noemi Reguart Hossein Borghaei, DO Nicolas Girard Frank Griesinger Dr Riyaz Shah Martin Reck Lizza Hendriks and more!

.Charlie Rudin shared promising DeLLphi-304 trial data on tarlatamab at #ASCO25. 🔗 Full highlights in ILCN: bit.ly/4leYUxC #LCSM

Felicidades!!!!

Active agent, response rate 46% with more importantly a better side effect profile than most other options. FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations | FDA fda.gov/drugs/resource…

👉 The ESMO Asia Congress 2025 takes place in Singapore, 5–7 December. Connect with oncology professionals and explore the latest developments for cancer care in the region. ⏰Early registration is available until 3 September. #ESMOAsia25 🔗 ow.ly/vJV450WjOFm

The latest episode of the IASLC podcast previews the upcoming #WCLC25 meeting with the four co-chairs: Drs. Jarushka Naidoo Umberto Malapelle Isabelle Opitz Noemi Reguart being held September 6-9, 2025 in Barcelona. Registration open now! iaslc.org/iaslc-news/lun…

📣 #ESMO25: The place where oncology leaders meet to explore the future of oncology. Register today! ⏰ Early registration deadline: 16 July 2025 🔗 ow.ly/jysG50Wfv3p

International Association for the Study of Lung Cancer (IASLC) - What Attendees Can Expect from WCLC25 Narjust Florez, MD, FASCO Stephen V Liu, MD Umberto Malapelle Jarushka Naidoo Noemi Reguart oncodaily.com/blog/wclc25-32… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc

Very important adjustment to FLAURA2 reimbursement in NHS England ; allowing early initiation of TKI while the chemo gets set up. Brilliant initiative by the cancer drugs fund team. BTOG #EGFR EGFR Positive Lung Cancer UK

In the Diary of an Oncology Leader video series by #ESMOW4O Marina Garassino shares the key lessons that continue to influence her leadership style 👉 Stay tuned for the next episode featuring Angela Lamarca 🔗 ow.ly/iC0350Wp6Oe #ESMODailyReporter #OncologyLeadership

Hot off the press a 🚨 Must-read review on optimizing treatment for #LungCancer with activating EGFR mutations , a true game changer in targeted therapy. TKIs have transformed outcomes, but the journey continues. 👉 acsjournals.onlinelibrary.wiley.com/doi/full/10.33… thanks to all the co-authors, great team

Datopotamab deruxtecan is now FDA approved for EGFR-mutant #NSCLC after prior EGFR & platinum therapy. In this episode of #LungCancerConsidered, Narjust Florez, MD, FASCO and Jacob sands break down the data and clinical implications of this exciting development. 🎧

📢 The updated ASCO Living Guidelines for NSCLC without a driver alteration are now published in Journal of Clinical Oncology! We reviewed key new data including HARMONI-2, NIPPON, and more. Balazs Halmos Dwight Owen ascopubs.org/doi/10.1200/JC…

🔥BREAKING🆙 Positive OS‼️ ✅FLAURA2: Osimertinib + Chemo vs Osimertinib 🎯"Statistically significant and clinically meaningful improvement in the key secondary endpoint of OS" 🗣️AstraZeneca OncoAlert LARVOL #EGFR EGFR Resisters astrazeneca.com/media-centre/p…

And there we have it. Final confirmation that F2>F1 making it the defecto SOC while we await other approvals. Great that this is reimbursed in ⁦NHS England⁩ ⁦BTOG⁩ ⁦EGFR Positive Lung Cancer UK⁩ astrazeneca.com/media-centre/p…